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MaBACKGROUND Heme oxygenase-1 (HO-1) is an inducible stress-responsive enzyme converting heme to bilirubin,
carbon monoxide, and free iron, which exerts anti-inﬂammatory and antiapoptotic effects. Although efﬁcient cardio-
protection after HO-1 overexpression has been reported in rodents, its role in attenuating post-ischemic inﬂammation is
unclear.
OBJECTIVES This study assessed the efﬁcacy of recombinant adenoassociated virus (rAAV)-encoding human heme
oxygenase-1 (hHO-1) in attenuating post-ischemic inﬂammation in a murine and a porcine ischemia/reperfusion model.
METHODS Murine ischemia was induced by 45 min of left anterior descending occlusion, followed by 24 h of reper-
fusion and functional as well as ﬂuorescent-activated cell sorting analysis. Porcine hearts were subjected to 60 min of
ischemia and 24h of reperfusion before hemodynamic and histologic analyses were performed.
RESULTS Human microvascular endothelial cells transfected with hHO-1 displayed an attenuated interleukin-6 and
intercellular adhesion molecule 1 expression, resulting in reduced monocytic THP-1 cell recruitment in vitro. In murine left
anterior descending occlusion and reperfusion, the post-ischemic inﬂux of CD45þ leukocytes, Ly-6Gþ neutrophils, and
Ly-6Chigh monocytes was further exacerbated in HO-1-deﬁcient hearts and reversed by rAAV.hHO-1 treatment. Con-
versely, in our porcine model of ischemia, the post-ischemic inﬂux of myeloperoxidase-positive neutrophils and CD14þ
monocytes was reduced by 49% and 87% after rAAV.hHO-1 transduction, similar to hHO-1 transgenic pigs. Functionally,
rAAV.hHO-1 and hHO-1 transgenic left ventricles displayed a smaller loss of ejection fraction than control animals.
CONCLUSIONS Whereas HO-1 deﬁciency exacerbates post-ischemic cardiac inﬂammation in mice, hHO-1 gene therapy
attenuates inﬂammation after ischemia and reperfusion in murine and porcine hearts. Regional hHO-1 gene therapy
provides cardioprotection in a pre-clinical porcine ischemia/reperfusion model. (J Am Coll Cardiol 2015;66:154–65)
© 2015 by the American College of Cardiology Foundation.m the *Medizinische Klinik I, Klinikum Grosshadern, Ludwig Maximilian University, Munich, Germany; yInstitute for Car-
vascular Prevention, Ludwig Maximillian University, Munich, Germany; zMedizinische Klinik I, Klinikum Rechts der Isar,
chnical University of Munich, and German Center for Cardiovascular Research, partner site Munich Heart Alliance, Munich,
rmany; xInstitute of Farm Animal Genetics, Friedrich-Loefﬂer-Institut, Mariensee, Germany; kDepartment of Medicine 2, Center
Thrombosis and Hemostasis Mainz and German Center for Cardiovascular Research, partner site Rhine Main, Mainz, Germany;
d the {Walter-Brendel-Centre for Experimental Medicine, Munich, Germany. This study was funded by the German Research
undation (SFB-TRR 127 to Drs. Hinkel, Petersen, Reichart, Niemann, and Kupatt), the German Center for Cardiovascular
search, the German Ministry for Education and Research (01EO1003 to Dr. Wenzel, BMBF01GU1105 to Dr. Kupatt), and an
titutional grant of the Klinikum to Dr. Gottlieb (FöFoLe). The authors have reported that they have no relationships relevant
the contents of this paper to disclose. Drs. Hinkel, Lange, and Petersen contributed equally to this work.
ten to this manuscript’s audio summary by JACC Editor-in-Chief Dr. Valentin Fuster.
nuscript received February 6, 2015; revised manuscript received April 1, 2015, accepted April 13, 2015.
AB BR E V I A T I O N S
AND ACRONYM S
AAR = area at risk
CD = cluster of differentiation
EF = ejection fraction
hHO = human heme oxygenase
HMEC = human microvascular
endothelial cell
HO = heme oxygenase
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155H eme proteins, such as mammalian hemo-globin and myoglobin, are central to oxy-gen transport and storage. However, with
an ischemic crisis, heme protein catabolism may
become crucial to avoid accumulation of heme, a
proinﬂammatory damage signal (1). Coincidentally,
heme catabolism produces biliverdin, a potential
scavenger of reactive oxygen species, and carbon
monoxide, which modulates excessive inﬂammatory
activation (2).SEE PAGE 166
I/R = ischemia and reperfusion
LAD = left anterior descending
LV = left ventricular
MPO = myeloperoxidase
rAAV = recombinant
adenoassociated virus
tg = transgenic
TLR = toll-like receptor
WMSI = wall motion score
index
= zinc protoporphyrinAccordingly, previous evidence suggests that heme
oxygenase-1 (HO-1) may serve as a therapeutic agent
in case of myocardial infarction. In rats, transduction
of a wild-type adenoassociated virus (AAV) 2 vector
encoding for human heme oxygenase-1 (hHO-1)
ameliorated post-ischemic remodeling and function
over 12 months of chronic ischemia inﬂicted by
permanent coronary occlusion (3) as well as repetitive
ischemia models (4). Moreover, HO-1-transgenic (tg)
mice displayed less cardiomyocyte loss and left ven-
tricular (LV) impairment after chronic left anterior
descending (LAD) artery occlusion than nontrans-
genic control mice (5). Thus, HO-1 improves late car-
diac remodeling post-infarction by regenerative
monocytes (6) and ﬁbroblasts (7).
In contrast, acute ischemia and reperfusion (I/R)
implies an enhanced variant of post-ischemic
inﬂammation caused by reperfusion-related rapid
inﬂux of well-oxidized blood carrying damaging
inﬂammatory cells to the central ischemic area.
Damage-associated molecular patterns from the
injured myocardium and extracellular matrix activate
membrane-bound toll-like receptors (TLR), inducing
a proinﬂammatory state in cardiomyocytes and adja-
cent endothelial cells in concert with extracellular
reactive oxygen species (8,9). Neutrophils are
recruited to acutely activated endothelium as in-
ﬂammatory ﬁrst responders, subsequently trans-
migrating to the myocyte compartment and exerting
tissue damage via myeloperoxidase (MPO) and pro-
teolytic enzymes (10). This cytotoxic effect may add
to infarct expansion by overwhelming inﬂammation
(9), in particular in scenarios of I/R, which re-
establishes central perfusion of the necrotic core
distal to the occlusion site. Moreover, neutrophils
actively induce the subsequent phagocytotic phase of
inﬂammation (11), mediated by monocytes and mac-
rophages, to allow for the later repair phase and res-
olution of inﬂammation (9). This time course of
inﬂammation is mirrored by a sequence of predomi-
nant inﬂammatory cell subsets in murine hearts:
Ly-6Gþ neutrophils give way to Ly-6Chigh monocytes,which are followed by angiogenic and
regenerative Ly-6Clow monocytes (12).
Although modulation of early post-
ischemic inﬂammation may limit infarct
expansion, targeting leukocyte recruitment is
notoriously difﬁcult because of the high
redundancy of inﬂammatory systems (13).
Conversely, attenuation of the early cytotoxic
phase of post-ischemic inﬂammation seems
an attractive target, which HO-1 may readily
provide. This notion is supported by the
reduction in cluster of differentiation (CD)
45þ cell invasion in histological samples of
HO-1.tg mice subjected to I/R (14).
However, the effect of HO-1 on proin-
ﬂammatory or regenerative leukocyte subsets
recruited to the post-ischemic heart has not
yet been investigated. In human or porcine
models, MPO-positive (MPOþ) cells represent
murine Ly-6Gþ neutrophils, whereas CD14high
cells resemble proinﬂammatory monocytes
and CD14 CD16þ monocytes may constitute the
proangiogenic population (12). Because HO-1 has been
reported to inhibit leukocyte adhesion during
inﬂammation in the heart (15) and other organs (16),
we sought to investigate its role in modulating I/R
inﬂammation in murine and porcine myocardial I/R
models.
METHODS
Recombinant rAAV.hHO-1 was produced using the
triple transfection method as described previously
(17). Human microvascular endothelial cells (HMECs)
were activated by lipopolysaccharide, 200 ng/ml for
6 h; then either supernatant was assessed for
interleukin-6 secretion by enzyme-linked immuno-
sorbent assay (R&D Systems, Inc., Wiesbaden, Ger-
many) or cells were incubated with an intercellular
adhesion molecule-1 antibody (sc-1511, Santa Cruz
Biotechnology, Inc., Heidelberg, Germany) and a
secondary antibody (sc-2014, Santa Cruz) before
ﬂuorescent-activated cell sorting analysis.
Ibidi-slides (ibiTreat VI0.4, Martinsried, Germany)
were seeded with HMECs pre-treated either with
lipofectamine-coated plasmids for empty backbone
(pcDNA) or hHO-1, with or without coapplication of
the HO-1 blocker zinc protoporphyrin (ZnPP). After
24 h, when cell layer was conﬂuent, human umbili-
cal vein endothelial cells were stimulated with
lipopolysaccharide, 200 ng/ml or high mobility
group box 1, 5 mg/ml for 1.5 h. Then, THP-1 mono-
cytic cells were superfused at a concentration of
750,000 cells/ml and at a shear rate of 0.57 ml/min
ZnPP
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sachusetts). After 8 min of cell superfusion and
1 min of washing with medium only, adherent cells
were counted.
Myocytic HL-1 cells and HMECs were cultivated
in Claycomb medium or Dulbecco’s modiﬁed Eagle
medium (plus 10% fetal calf serum, plus 1% peni-
cillin/streptomycin), respectively. HL-1 cells were
transfected using Satisfection (TPP AG, Trasadin-
gen, Switzerland) according to the manufacturer’s
protocol. Then, 48 h later, hHO-1-transfected cells
were plated on 24-well plates to undergo 18 h of
hypoxia (1% oxygen) followed by 4 h of reoxyge-
nation. Cell death was assessed via trypan blue
staining. Results are given as percentage of living
cells.
Total ribonucleic acid was extracted from the
control group, rAAV.hHO-1, and the hHO-1.tg groups,
treated with DNaseI (Invitrogen, Darmstadt, Ger-
many) and converted to complementary DNA. Quan-
titative real-time polymerase chain reaction was
performed with primer pairs for hHO-1.
Animal care and all experimental procedures were
performed in accordance with the Animal Care and
Use Committees of Bavaria, Rhineland-Palatinate,
and Lower Saxony, Germany. All pig experiments
were conducted at the Walter-Brendel Centre for
Experimental Medicine at the Ludwig Maximilian
University Munich and the Center for Thrombosis and
Hemostasis, University Medical Center Mainz.
Male C57BL/6, TLR4-/- on C57BL/6 background as
well as HO-1þ/þ, HO-1þ/-, and HO-1-/- mice (18) on a
mixed C57BL/6/129sv/Balb-C background (8 to 12
weeks old) underwent either myocardial I/R injury or
sham operation. A total of 5  1012 virus particles of an
rAAV-encoding hHO-1 were injected into the tail vein
14 days before further instrumentation, where indi-
cated (Online Figure 1A). Mice were anesthetized and
mechanically ventilated. Ischemia injury was induced
by occlusion of the LAD coronary artery with an 8-0
polypropylene suture. After ischemic injury for
45 min, the occluding suture was opened and the
myocardium reperfused for 24 h. Sham mice under-
went the same procedure but without coronary artery
ligation.
Reperfusion was then allowed for 24 h, followed by
echocardiographic monitoring (Vevo 770 and 2100,
VisualSonics, Inc., Toronto, Canada; n ¼ 20 per
group). Parasternal long-axis views were obtained
for assessment of ejection fraction (EF). Validation of
the wall motion score index (WMSI) was adapted
from Zhang et al. (19). An 11-segment model of
WMSI based on 1 parasternal long-axis B-mode
view (5 segments: apical, mid-anterior, mid-inferior,basal-anterior, basal-inferior) and 1 mid-ventricular
parasternal short-axis B-mode view (6 segments:
anteroseptal, anterior, anterolateral, inferolateral,
inferior, inferoseptal) was calculated. Wall motion
was scored 1 for normal, 2 hypokinetic, and 3 akinetic.
WMSI was assessed as the sum of all scores divided
through the amount of evaluated segments. Wall
motion was considered abnormal at WMSI >1.4.
In a different set of experiments (n ¼ 6 per group),
pinhole single-photon emission computerized to-
mography measurement of infarct size (20) was
conducted 45 min after injection of 200 ml [99mTc]-
sestamibi (370 MBq, Cardiolite, Bristol-Myers Squibb
Medical Imaging Inc., Munich, Germany) via tail vein.
Mice were positioned in the center ﬁeld of the gamma
camera and scanned for 30 min.
Invasive monitoring of LV function was performed
under intravenous anesthesia (n ¼ 7 per group) with a
pressure tip catheter (Millar, Inc., Houston, Texas).
The catheter was advanced through the left carotid
artery and aorta into the LV under continuous moni-
toring of the pressure curves until the diastolic pres-
sure indicated localization in the LV (21).
Ten-milligram pieces of post-ischemic hearts
were digested with collagenase II (1 mg/ml)/DNase (50
mg/ml), pressed through a cell strainer (70 mm), and
centrifuged at 300 g. After discarding the supernatant,
red blood cells were lysed with an ammonium-
potassium buffer, washed twice, and stained for
viability (trypan blue). After resuspension of the cell
pellet and unspeciﬁc Fc binding blockade (2% fetal calf
serum, CD16/32), cells were stained with speciﬁc anti-
bodies for CD45.2, CD11b, CD3, Ly-6C, and Ly-6G for
15 min, washed twice, and transferred to ﬂuorescent-
activated cell sorting tubes.
hHO-1.tg pigs were generated as described previ-
ously (22). Cloned syngenic offspring were used for
the acute myocardial infarction pig model (Online
Figures 1B and 2).
Twenty-one days before I/R injury, the myocar-
dium was transduced with hHO-1 by selective pres-
sure regulated retroinfusion of 1  1013 rAAV.hHO-1
particles into the anterior ventricular vein, which
anatomically drains the LAD-perfused myocardium
(23,24). Three weeks later, the I/R injury protocol
was performed.
Pigs (n ¼ 5 per experimental group) were anes-
thetized. Access to vessels and catheterization were
performed as previously described (25).
EF and LV end-diastolic pressure measurements
were performed before ischemia and after 24 h of
reperfusion. Additionally, regional myocardial func-
tion was obtained at 24 h of reperfusion via ultrasound
crystals (Sonometrics Corporation, Ontario, Canada).
FIGURE 1 hHO-1 Limits Inﬂammatory Activation of Endothelial Cells
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oxygenase-1 (hHO-1) transfection, unless the HO-1 inhibitor zinc protoporphyrin (ZnPP) was coapplied. (B) The leukocyte adhesion molecule
intercellular adhesion molecule (ICAM)-1 was up-regulated by LPS, whereas hHO-1 overexpression attenuated the response. ZnPP blocked the
effect of hHO-1. Examples (C) and quantitative analysis (D) of THP-1 cell adhesion under venular shear stress (1 dyne/s, scale bar 100 mm),
which was increased after LPS; hHO-1-transfection reduced THP-1 adhesion, unless inhibited by ZnPP. (E and F) High mobility group box 1
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FIGURE 2 Effect of HO-1 on Murine Post-Ischemic Inﬂammation
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(A), CD11bþ (B), Ly-6Gþ neutrophilic (C), and Ly-6Chigh (D) proinﬂammatory monocyte
cells, compared with HO-1þ/þ hearts. These alterations were attenuated by application of
recombinant adenoassociated virus (rAAV)-encoding hHO-1. (E) No difference was found
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*p < 0.05, **p < 0.001. Abbreviations as in Figure 1.
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158Subendocardial segment shortening was assessed
in the ischemic and nonischemic region at rest and
under increased heart rate (120 and 150 beats/min).
Infarct size was assessed via methylene blue
exclusion and tetrazolium red viability staining (26).
Before explantation of the heart, the LAD was ligated
at the site of infarct induction and methylene blue
injected into the LV. After excision of the heart
tissue samples of the infarct area, the area at risk
(AAR), and the control region were harvested for
terminal deoxynucleotidyltransferase dUTP nick end
labeling assay, capillary staining, viability staining
(tetrazolium red), and CD14-staining, as well as
MPO assay.The MPO assay was performed for evaluation of
leukocyte inﬂux in the ischemic area (AAR and
infarct) (27). Tissue from the AAR was analyzed for
capillary density (PECAM-1, Santa Cruz) staining of
slices 2 and 3 (23). Apoptosis detection (ApopTag Kit,
Millipore, Schwalbach, Germany) was done according
to the manufacturer protocol in the ischemic AAR and
the nonischemic control area. Nuclei were counter-
stained with 40,6-diamidino-2-phenylindole (Vector
Laboratories, Burlingame, California).
STATISTICAL METHODS. The results are given as
mean  SEM. Statistical analyses were performed via
1-way analysis of variance. When a signiﬁcant effect
was obtained with analysis of variance, usually the
multiple comparison test between the groups with
the Student-Newman-Keuls test was performed.
However, for WMSI analysis, the nonparametric
Kruskal-Wallis test was used. For the interleukin-6
enzyme-linked immunosorbent assay and the apo-
tosis index, Dunnett-T3 test was used because of the
variance heterogeneity. A p value <0.05 was consid-
ered signiﬁcant.
RESULTS
To determine whether HO-1 would affect endothelial
activation during post-ischemic inﬂammation, we
assessed inﬂammatory activation and function of
HMEC. We found that inﬂammatory stimulation
of endothelial cells resulted in increased expression
of cytokines, such as interleukin-6 (Figure 1A), and
adhesion molecules, such as intercellular adhesion
molecule-1 (Figure 1B). Plasmid transfection of hHO-1
blunted expression of both inﬂammatory proteins.
Moreover, recruitment of monocytic THP-1 cells was
analyzed in vitro under venular shear stress, such as
occurring during ﬁrm adhesion in vivo (28). Here,
hHO-1 decreased the number of THP-1 cells adhering
on human endothelial cells after stimulation with
lipopolysaccharide (Figures 1C and 1D), as well as high
mobility group box 1 (Figures 1E and 1F).
To assess the impact of HO on post-ischemic
inﬂammation in vivo, we ﬁrst compared HO-1-
deﬁcient mice and wild-type siblings, which were
subjected to 45 min of LAD ligation and 24 h of
reperfusion (Online Figure 1A). There was a 3-fold
increase of CD45.2þ leukocytes into the ischemic
area in HO-1-deﬁcient mice compared with control
animals (14.9  3.6  103 vs. 4.8  1.8  103 cells/mg
tissue, respectively) (Figure 2A). CD11bþ leukocytes
were increased more than 6-fold in HO-1-/- hearts (10.0
 2.3  103 cells/mg) than in control animals (1.6  0.3
 103 cells/mg), with HO-1 heterozygous hearts dis-
playing an intermediate level (3.9  0.5  103 cells/mg)
FIGURE 3 Effect of HO-1 in Murine Ischemia and Reperfusion
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159(Figure 2B). Consistently, homozygous HO-1-deﬁcient
hearts recruited more Ly-6G-positive neutrophils (7.1
 1.3  103 cells/mg) than control and heterozygous
hearts (1.0  0.2  103 and 3.0  0.6  103 cells/mg,
respectively) (Figure 2C). This pattern was replicated
for proinﬂammatory Ly-6Chigh monocytes (3.0  0.6 
103 cells/mg) but not heterozygous (1.2  0.2  103
cells/mg) and control siblings (0.8  0.3  103 cells/
mg) (Figure 2D). In contrast, no signiﬁcant difference
was found when we analyzed Ly-6Clow proangiogenicmonocytes (Figure 2E). Of note, rAAV transduction of
hHO-1 in HO-1-deﬁcient mice attenuated the
increased recruitment of CD45.2, CD11bþ, Ly-6G, and
Ly-6Chigh cells (Figures 2A to 2D). Moreover,
rAAV.hHO-1 reduced Ly-6G and increased Ly-6Clow
cells in wild-type mice, compared with rAAV.GFP
(Online Figures 3A to 3F). Taken together, HO-1 deﬁ-
ciency increased post-ischemic inﬂammation, in
particular of neutrophil and Ly-6Chigh monocytic cell
inﬁltration.
FIGURE 4 hHO-1 Affects Post-Ischemic Inﬂammation
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a signiﬁcant increase of hHO-1 in hHO-1 transgenic (hHO-1.tg) as well as in rAAV.hHO-1-
treated pigs (n ¼ 3 per group). (B) Recruitment of myeloperoxidase-positive (MPOþ)
leukocytes to the infarct area was signiﬁcantly increased in the infarct region of control
animals. hHO-1.tg pigs displayed an attenuated leukocyte recruitment, unless ZnPP was
coapplied. Transduction of cardiomyocytes with rAAV.hHO-1 mimicked the effect of hHO-1
transgenic hearts. (C) Examples of CD14þ macrophages in the noninfarcted area at risk of
control and hHO-1 transgenic animals. (D) Quantitative analysis revealed a signiﬁcant
decrease of CD14þ cells/hpf in hHO-1.tg and rAAV.hHO-1 transduced hearts, unless ZnPP
was coapplied. Scale bar ¼ 50 mm. Mean  standard error of the mean; n ¼ 5; *p < 0.05,
**p < 0.001. Abbreviations as in Figures 1 and 2.
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160Consistently, assessing hypokinetic or akinetic
areas with an echocardiographic WMSI (19,29)
demonstrated an increase in infarct size in HO-1-
deﬁcient mice (Figure 3A), which was not detect-
able in 2-dimensional echocardiography (Figure 3B)
or in pinhole single-photon emission computerized
tomography analysis (Online Figures 3G and 3H).
Interestingly, rAAV.hHO-1 application increased
post-ischemic EF in wild-type mice compared with
rAAV.GFP (Online Figure 3F). In contrast, invasive
assessment of LV pressure did not reveal a signiﬁ-
cant decrease in HO-1-deﬁcient hearts at rest, with
or without rAAV.hHO-1 application (Figure 3C). An
additional challenge of the hearts with increasing
amounts of norepinephrine (25 to 100 ng boli
intravenously) unmasked a lack of contractile
responsiveness in HO-1-/- hearts (Figure 3D), whichwas attenuated by rAAV.hHO-1 application. Consis-
tent with these results, terminal deoxynucleotidyl-
transferase dUTP nick end labeling–positive nuclei
were found at higher rates in HO-1-deﬁcient mouse
hearts (Figures 3E and 3F). Of note, TLR4 deﬁciency
did not alter functional impairment signiﬁcantly
(Online Figure 4). Thus, in the absence of HO-1, we
found a small but signiﬁcant impairment of
myocardial infarct size, which did not affect
myocardial function at rest but decreased functional
LV reserve under adrenergic stimulation.
We next analyzed the effect of HO-1 on post-
ischemic inﬂammation in pigs, subjecting por-
cine hearts to 1 h of ischemia (LAD occlusion)
followed by 24 h of reperfusion. In addition to
transgenic pigs overexpressing human HO-1, we
applied an AAV encoding for hHO-1 (rAAV.hHO-1)
with a similar hHO-1 expression level (Figure 4A,
Online Figure 1B) or an rAAV.LacZ control vector via
retroinfusion.
Compared with the normoxic region and the non-
infarcted AAR, a massive inﬂux of MPOþ neutrophils
was observed in the infarct area (10.1  1.3  103 vs.
0.8  0.1  103 cells/mg normoxic area, 2.1  0.7  103
cells/mg AAR) (Figure 4B, Online Figure 5). Over-
expression of hHO-1 in transgenic animals signiﬁ-
cantly reduced the recruitment of MPOþ cells (4.7 
1.3  103 cells/mg), whereas HO-1 inhibition (ZnPP)
reset the level of MPOþ cells in the infarct zone to that
of wild-type animals (10.3  0.9  103 cells/mg). Of
note, regional treatment of the ischemic myocardium
with rAAV.hHO-1 sufﬁced to reduce the MPOþ cell
inﬂux by 46% (5.3  1.1  103 cells/mg) (Figure 4B).
Accordingly, proinﬂammatory CD14þ monocytes
were accumulating in the infarcted area (480  39
cells/mm2) of wild-type hearts (Figures 4C and 4D).
This effect was largely reduced by hHO-1 over-
expression: in rAAV.hHO-1-treated hearts, we found
61  16 cells/mm2 and in hHO-1.tg hearts 98  20 cells/
mm2, unless ZnPP was coapplied (453  37 cells/mm2)
(Figures 4C and 4D).
Ischemic and inﬂammatory processes inﬂict
abrogation of functional capillaries in the ischemic
area. Because microvascular density is closely
correlated to residual post-ischemic function, we
analyzed capillary densities in the infarct border
zone. In rAAV.hHO-1 and HO-1.tg hearts, the level of
CD31þ capillaries was more than double that of
control hearts (Online Figures 6A and 6B), unless the
HO-1 inhibitor ZnPP was added to hHO-1.tg hearts.
This effect might still be initiated by hHO-1-
transduced cardiomyocytes, because the condi-
tioned medium of hHO-1-transfected cardiomyocytic
HL-1 cells increased endothelial cell survival after
FIGURE 5 hHO-1 Affects Infarct Size in Porcine Ischemia-Reperfusion
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J A C C V O L . 6 6 , N O . 2 , 2 0 1 5 Hinkel et al.
J U L Y 1 4 , 2 0 1 5 : 1 5 4 – 6 5 HO-1 and Cardioprotection in Ischemia
161hypoxia/reoxygenation, a surrogate parameter for
capillary preservation after I/R in vivo (Online
Figures 6C and 6D).
In this model, infarct size of control hearts (55  5%
AAR) was signiﬁcantly reduced by rAAV.hHO-1
retroinfusion (41  3%), similar to hHO-1.tg pigs
(35  4%) (Figures 5A and 5B). Consistently, the car-
dioprotection of hHO-1.tg pigs was reversed by
regional application of the speciﬁc HO-1 inhibitor
ZnPP (61  3% infarct size) (Figures 5A and 5B). The
AAR of these groups did not differ in our study
(Figure 5C). Of note, terminal deoxynucleotidyl-
transferase dUTP nick end labeling–positive cell
death was signiﬁcantly reduced in the hHO-1-
overexpressing pigs at 24 h, unless HO-1 was inhibi-
ted by ZnPP (Figure 5D). In particular, cardiomyocyte
and endothelial apoptosis was prevented by hHO-1
(Online Figure 7).
According to the structural impact of our I/R pro-
tocol, the difference between pre- and post-ischemic
LVEF varied signiﬁcantly, although the pre-ischemiclevels did not vary among groups (Online
Figure 8A). In rAAV.LacZ-treated control animals,
change in EF was 28  3% (Figure 6A). This I/R-
induced loss of function was attenuated in both
hHO-1-overexpressing groups, either rAAV.hHO1-
treated (17  2%) or hHO-1.tg pigs (16  2%). Howev-
er, retroinfusion of the HO-1 inhibitor ZnPP abrogated
the functional beneﬁt of hHO-1.tg pigs (27  2%).
Similarly, the post-ischemic increase in change in EF
and LV end-diastolic pressure (3.1  0.6 mm Hg in
control animals) decreased to 0.3  0.5 mm Hg (hHO-
1.tg) and 1.1  0.5 mm Hg (rAAV.hHO-1). The latter
effect was reversed by ZnPP (3.8  0.6 mm Hg)
(Figure 6B, Online Figure 8B).
This improvement in global systolic function was
mirrored in regional myocardial function of non-
infarcted AAR. Here, rAAV.LacZ-treated control
hearts displayed 25  5% of the myocardial short-
ening in the nonischemic control region at rest,
worsening to akinesia (2  4%) under the challenge of
rapid atrial pacing (150 min) (Figure 6C). Human
FIGURE 6 Functional Impact of hHO-1
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162HO-1.tg hearts demonstrated a signiﬁcant higher
preservation of functional reserve at rest (58  5%)
as well as under atrial pacing of 150 beats/min
(44  8%). Antagonizing HO-1 via ZnPP blocked the
increase in regional myocardial function of hHO-1.tg
pig hearts (3  4%). Of note, rAAV.hHO-1 trans-
duction, displaying no difference to control hearts
at rest, signiﬁcantly increased regional myocardial
function at 150 beats/min (37  5%). Thus, exogenous
supply of hHO-1 to cardiomyocytes reduces cellular
damage and death and protects post-ischemic
function. Taken together, an enhanced abundance of
HO-1 in hHO-1.tg hearts and rAAV.HO-1-transduced
hearts seems to improve cardiomyocyte survival
and function. Both coincide with attenuation ofpost-ischemic inﬂammation and improved micro-
vessel preservation.
DISCUSSION
Recently, inﬂammatory events have been scrutinized
for their impact on cardiac I/R injury. Besides the
composition and origin of invading inﬂammatory cells
(6), the amount of cells and the kinetics of their
recruitment seem to determine the expansion of the
ﬁbrotic scar and the cardiac remodeling accompanying
its establishment (30). Therefore, we asked whether
HO-1, known for its immunomodulatory properties in
cell culture (31,32) and in xenotransplantation (22,33),
is capable of altering the post-ischemic immune
response and subsequent functional outcome in car-
diac I/R injury.
In vitro, HO-1 sufﬁces to blunt inﬂammatory
activation of endothelial cells in culture, thereby
limiting their potential to recruit inﬂammatory
monocytes under ﬂow conditions (Figure 1). In vivo,
post-ischemic inﬂammatory cell inﬂux increased in
HO-1-deﬁcient mice: neutrophilic Ly-6Gþ and proin-
ﬂammatory monocytic Ly-6Ghigh subsets were re-
cruited at higher rates to murine hearts after 45 min
of ischemia and 24 h of reperfusion, when HO-1 was
absent (Figure 2). Moreover, LV wall motion, func-
tional reserve, and apoptosis were all impaired in
HO-1-/- animals (Figure 3).
In porcine I/R studies, ubiquitous transgenic
overexpression and regional AAV transduction of HO-
1 both achieved similar levels of inﬂammation control
(Figure 4), consistent with decreased infarct size
(Figure 5) and improved LV function (Figure 6). Of
note, the recombinant AAV2/9 regionally applied in
this study primarily targets cardiomyocytes (34,35),
with minimal contamination of endothelial cells or
macrophages found in tomato reporter gene mice
(data not shown). This observation carries the impli-
cation that rAAV.HO-1-based gene therapy mainly
targets intracardiac processes that initiate recruit-
ment of neutrophils and inﬂammatory monocytes as
well as functional impairment. In contrast, additional
effects of HO-1 on extracardiac targets (e.g., in
circulating leukocytes of the transgenic, ubiquitously
HO-1-overexpressing pigs) do not seem essential for
HO-1-mediated cardioprotection.
This argues for a central relevance of the
myocardium itself as target of HO-1-mediated car-
dioprotection and origin of post-ischemic inﬂamma-
tory signaling, and renders endothelial protection
and angiogenesis as secondary processes. We con-
sistently observed a distinct anti-inﬂammatory effect
of HO-1 in both models of I/R. We followed a potential
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A resting state is deﬁned by low ROS and an anti-adhesive, inactive endothelium. Inﬂammatory activation induces ROS production, chemokine and adhesion
molecule upregulation, leukocyte recruitment, and apoptosis. Heme oxygenase-1 (HO-1) is capable of reversing inﬂammatory activation toward the resting
state. ICAM ¼ intercellular adhesion molecule; PMN ¼ polymorphonuclear neutrophils; ROS ¼ reactive oxygen species.
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163interaction of HO-1 with TLR4 (36,37), a receptor for
damage-associated molecular patterns, such as high
mobility group box 1 (38). the latter being released
from ischemic cardiomyocytes (39). However, neither
inﬂammatory cell inﬂux nor function was signiﬁ-
cantly altered in TLR4-deﬁcient mice in our I/R model
(Online Figure 4).
In the porcine model, the functional impact in
hHO-1-constrained post-ischemic inﬂammation was
already apparent at rest (Central Illustration), whereas
in HO-1-/- mice functional impairment was unmasked
solely on adrenergic stimulation. Of note, diabetes
mellitus, which inﬂicts chronic vascular inﬂamma-
tion, further exacerbates infarct size in HO-1-deﬁcient
mice in a 60-min LAD occlusion model (40). We could
obtain an increased infarct size only with the sensitive
WMSI (Figure 3A), but not with pinhole single-photon
emission computerized tomography measurement
(20) (Online Figures 3G and 3H), most likely because
of a limited spatial resolution of 1.9 mm. Accordingly,
hHO-1.tg mice display infarct size reduction after
60 min of ischemia (14), similar to our porcinemodels
of hHO-1 overexpression (Figure 5). Besides the time
sensitivity, structural differences, regional application
of the rAAV.hHO-1 vector, and a more neutrophil-
prone immune system, with 11-25G/l neutrophils
circulating in blood without inﬂammatory stimula-
tion, may have contributed to a more robust hHO-1
effect in the porcine model.The anti-inﬂammatory potential of HO-1 has pre-
viously been revealed in heart transplantation (41),
although that adaptive immune reaction differs from
innate immune reactivity in post-ischemic inﬂam-
mation. For the latter, the composition of leukocyte
inﬂux is of particular interest, because a well-
orchestrated sequence of proinﬂammatory and anti-
inﬂammatory events takes place in post-ischemic
cardiac repair: neutrophil and proinﬂammatory Ly-
6Chigh monocytes catabolize cell debris and pave
new avenues for anti-inﬂammatory, proangiogenic
Ly-6Clow monocytes and myoﬁbroblasts to form a
residual tissue wall and provide blood supply
therein. However, current reperfusion therapies may
overwhelm the heart with leukocyte inﬂux via the
infarct artery, an avenue permanently occluded in
the natural disease course (9). This early proin-
ﬂammatory cell inﬂux is reduced when HO-1 is
overexpressed, improving functional outcome in the
porcine model. In contrast, regenerative monocyte
recruitment was unaffected by modulation of HO-1
(Figure 2).
STUDY LIMITATIONS. Although we have demon-
strated successful treatment of I/R injury in a pre-
clinical porcine model, we are aware that the use of
young, healthy animals does not necessarily reﬂect
the treatment efﬁcacy in elderly, cardiovascular risk-
factor exposed patients. Moreover the pre-treatment
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164with recombinant AAV vector as conducted in this
study does not cover its application as adjuvant
therapy in the treatment of acute myocardial infarc-
tion, where rapid activation of HO-1 may require a
different approach.PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: HO-1
attenuates post-ischemic cardiac inﬂammation, and
regional rAAV-encoding human HO-1 gene therapy
improves ventricular ejection fraction in animalmodels.
TRANSLATIONAL OUTLOOK: Further studies are
needed to determine whether strategies that activate
HO-1 might have clinical value for prevention or treat-
ment of ischemia-reperfusion injury in thehumanheart.CONCLUSIONS
We have demonstrated that HO-1 overexpression
limits proinﬂammatory activation of ischemia-
challenged cardiomyocytes and inﬂammatory cell
inﬂux in reperfused murine and porcine hearts.
Enhancing HO-1 activity in early reperfusion im-
proves post-ischemic function in a pre-clinical pig
model and seems a suitable approach to treat post-I/R
injury.
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